FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial

​

Quoin Pharmaceuticals has received FDA clearance for its IND application for QRX003, enabling it to initiate a Phase II clinical trial for a treatment for Peeling Skin Syndrome (PSS).

The post FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial appeared first on Hospital Management.

 

Back to the Featured Stories
FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial

Featured Stories

FDA clears Medtronic’s LigaSure RAS Maryland device
SpliSense begins Phase IIb SPL84 trial for cystic fibrosis
Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy
Hyperfine concludes Contrast PMR study enrolment for Swoop MRI system
Arrowhead reports top-line results in mixed hyperlipidaemia trial

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us